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Summary
Using in situ hybridization, we have shown that activated human peripheral blood eosinophils
expressmRNA for granulocyte/macrophage colony-stimulating factor (GM-CSF) . Between 15
and 27% of eosinophils gave positive hybridization signals for GM-CSFmRNA after stimulation
with the calcium ionophore A23187 or interferon -y, and 4 and6% after incubation with interleukin
3 (IL3) or ILS . Activated eosinophils also gave specific immunoreactivity with an anti-GM-CSF
polyclonal antibody; suggesting translation of the mRNA. These data indicate that eosinophils
may be an important source of GM-CSF at sites of allergic inflammation . Furthermore, the
identification ofGM-CSF production byhuman eosinophils suggests that the pro-inflammatory
potential of this cell type may be substantially greater than hitherto recognized .
C
ytokines of the l1r3, 11,4, IL5, and granulocyte/macro-
phage colony-stimulating factor (GM-CSF) gene cluster
may be important in the pathogenesis of atopic allergic inflam-
mation in man (1) . The production of these cytokines by ac-
tivated T lymphocytes (reviewed in reference 2) and mast cells
(3) has been well documented . The contribution ofeosinophils,
prominent cells in the inflammatory infiltrate in allergic dis-
ease, to cytokine release is not yet fully realised . The descrip-
tion of transforming growth factor ci (TGF-a) andIL1a pro-
duction by human and murine eosinophils, respectively (4,
5), lead us to explore the potential ofhuman eosinophils to
elaborate pro-inflammatory cytokines in allergy.
Eosinophils.
￿
These were obtained from the peripheral blood of
subjects with eosinophils of>8% (range, 8-70%) in association
with atopy, helminthic infection, or the hypereosinophilic syndrome .
The mean percentage eosinophil purity (as determined by Kimura
stain and confirmed by differential counts using May-Grunwald-
Giemsa) using discontinuous metrizamide gradients (6), was 95.4%
± 1.1 (range, 90.0-99.8%) . Neutrophils were the major con-
taminating cells.
Cell Stimulation .
￿
Eosinophils were incubated under sterile con-
ditions with either culture medium alone, A23187 (10-6 M),
r-IFN-y (500 or 1,000 U/ml), rhIL3, or rhIL5 (both at 300 U/ml)
(kind gifts from Dr. Paul Winter, Biogen Research Corp ., Cam-
bridge, MA ; BioTrans Inc., Los Angeles, CA ; and Dr. Colin San-
derson, National Institute for Medical research, Mill Hill, UK,
respectively) . The culture medium consisted ofRPMI 1640 sup-
plemented with 10% FCS, 50,uM 2-ME, 2 MM L-glutamine, 100
U/ml penicillin, 100 /cg/ml streptomycin, and 50 i~g/ml gentamycin.
A23817 stimulation was continued either for 60 min or 24 h (i.e .,
30-min incubation with A23187, after which cells were washed
once and incubated in fresh culture medium for 24 h) . IL3, IL5,
and IFN-y stimulation was for 24 or 48 h in culture medium .
Ribonucleotide vanadyl complex (20 mM ; Sigma Chemical Co .,
Poole, UK) was added to the cell suspension before preparing
cytospins to inactivate eosinophil ribonuclease (RNase) . Cytospins
were prepared on poly-L-lysine-coated slides, fixed in 4% parafor-
maldehyde in PBS, and washed twice in 15% sucrose in PBS .
In Situ Hybridization.
￿
In situ hybridization was performed as
previously described (7, 8) . Briefly, cDNA forGM-CSF was inserted
into a PGEM-1 . vector, linearized, and transcribed in the presence
of"S-UTP and T7 and SP6 RNA polymerases for antisense (com-
plementaryRNA) and sense (having identical sequence tomRNA)
riboprobes, respectively. Cells were permeabilized with proteinase K,
and nonspecific binding of "S was inhibited by 0 .1M triethanola-
mine, acetic anhydride, iodoacetamide, and N-ethylmaleimide . An-
tisense or sense probes (1-1.5 x 106 cpm/slide) in hybridization
buffer containing dithiothreitol (100 mM) were heated to 60°C
for 1 h before hybridization (16 h at 40°C) . During high strin-
gency (4-0 .1 x SSC at 45°-50°C) post-hybridization washings,
unhybridized single-strandedRNA was removed by RNase-A. Au-
toradiography was followed by counterstaining with either hae-
motoxylin, May-Grunwald Giemsa, or carbol chromotrope 2R .
PHA-stimulated (5 ug/ml) human mononuclear cells were used
as controls for GM-CSF mRNA` cells . Negative controls in-
cluded theGM-CSF sense probe and cytospins treated with RNase-A
solution before hybridizing with the antisense probe. As a further
control, cells were incubated with cold antisense probebefore adding
the "S-labeled antisense cRNA probe to compete for hybridiza-
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tion in the number of GM-CSF mRNA' cells. The percentage
ofpositive cells was determined by "blind" counting >1,000 cells/
cytospin, using an eyepiece graticule, as described (1) .
Immunocytochemistry . This was performed using the alkaline
phosphatase anti-alkaline phosphatase (APAAP) method as previ-
ously described (9) . A goat IgG anti-GM-CSF antibody (a-GM-
CSF ; British Bio-technology, Oxford, UK) was selected for its
ability to neutralize the bioactivity o£ both recombinant and nat-
ural humanGM-CSF with no crossreactivity with IlAce or 0, 11,2,
IL3, IIr4, IIr6, TNF-a, TNF-(3, or G-CSF. Cytospins were washed
in Tris-buffered saline (TBS), and a-GM-CSF was added at a final
concentration of 100 1Ag/ml and allowed to incubate overnight
(4°C) . Slides were briefly washed in TBS, APAAP-conjugated rabbit
anti-goat was added at 1:40 dilution, and developed with Fast Red.
PHA-stimulated mononuclear cells were used as a positive control.
An antigen absorption test resulted in a marked reduction in im-
munoreactivity ofa-GM-CSF in both IFN-y-activated eosinophils
and PHA-stimulated mononuclear cells in the presence of10 Frg/ml
of rhGM-CSF, indicating the specificity of the antibody.
Results and Discussion
Eosinophils incubated either with A23187 or recombinant
IFN-y, IL3, or IL -5 (cytokines that upregulate eosinophil
effector function) (10-12) gave clear hybridization signals with
theGM-CSF antisense probe (Table 1) . Negative signals were
obtained with the sense probe in all preparations examined .
After a 60-min incubation with A23187, 15.1% of the cells
were GM-CSF mRNA+ . This percentage increased to
27.3% after a 24-h incubation. With medium alone, only
0.5-1% were'GM-CSF mRNA+ . Both IL-3 and IL-5 in-
creased thenumber of GM-CSF mRNA+ from 1% to 6.1%
and 4.6%, respectively. After incubation with IFN-y (500
U/ml), 16.5% (24 h) and 18.7% (48 h) of the eosinophils
Table 1 .
￿
In Situ Hybridization ofHuman Eosinophils with
Riboprobes for Human GM-CSF
Two out of six experiments were 48-h incubation .
t One out of three experiments was 48-h incubation .
Percentage mRNA+ cells
GM-CSF probes
(mean ± SEM)
Immunoreactivity of human eosinophils with an anti-GM-CSF antibody
using APAAP . The counts represent mean ± SEM (n = 3) of percent-
age of positively staining cells .
expressed mRNA for GM-CSF. Increasing the concentration
of IFN-y to 1,000 U/ml over 48 h resulted in a further in-
crease in the percentage of mRNA' cells to 23.3%. The
identification ofmRNA for GM-CSF in activated, but not
resting, eosinophils suggests that the protein is not constitu-
tively expressed but induced after stimulation .
Both RNase pre-treatment of the eosinophil preparations
and competition experiments (using cold and radiolabeled
probes) resulted in a substantial reduction in the antisense
GM-CSF mRNA signal . These observations, together with
the negative hybridization observed with the sense probe,
confirm the specificity of the signal .
Evidence for translation ofGM-CSF mRNA in activated
eosinophils was obtained by immunocytochemical staining
with an a-human GM-CSF. Eosinophils incubated with
A23187 or IFN-y, but not medium alone, gave positive
staining (Table 2) .
The identification of picogram amounts of GM-CSF in
supernatants of Ionomycin-stimulatedhuman eosinophils, but
not controls (13), provides important additional evidence to
support the hypothesis that this cell type has the capacity
to synthesize, store, and secrete GM-CSF.
We were particularly careful to ensure that the GM-CSF
mRNA hybridization signals could not be attributable to
the small number of contaminating leukocytes (Fig. 1 A) .
A combination ofin situ hybridization with eosinophil-specific
staining (carbol chromotrope 2R) confirmed the localization
ofGM-CSF mRNA to eosinophils (Fig . 1, C andD) . Fur-
thermore, the mean purity of the eosinophils used in this
study was >95%, while the mean percentage of GM-CSF
mRNA+ cells was up to fourfold higher than the maximum
percentages of contaminating cells .
We recently demonstrated mRNA expression for the IL3,
IL4, IL-5, andGM-CSF gene cluster in allergen-induced late-
phase cutaneous reactions in atopic subjects (1) . Although
the T lymphocyte is considered to be a major source ofthese
cytokines, our data raise the possibility that infiltrating eo-
sinophils also contribute to the overall cytokine production
in allergic tissue reactions. Bearing in mind the well-established
association of eosinophils with asthma, the production of
cytokines by eosinophils may also be important in this dis-
ease . Human eosinophils have been shown to express and re-
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Cytokine mRNA and Immunoreactivity in Activated Human Eosinophils
Treatment Time n Antisense Sense
Medium alone 60 min 4 0.5% ± 0.2 0
A23187 (10-6 M) 60 min 6 15.1% ± 2.9 0
A23187 (10-6 M) 24 h 3 27.3% ± 6.4 0
Medium alone 24 h' 6 1.0% ± 0.14 0
IFN-y (500 U/ml) 24 h 6 16.5% ± 2.5 0
IFN-y (500 U/ml) 48 h 4 18.7% ± 1.1 0
IFN-y (1,000 U/ml) 48 h 3 23.3% ± 3.5 0
IL-5 (300 U/ml) 24 hi 3 4.6% ± 1 .2 0
IL-3 (300/ml) 24 ht 3 6.1% ± 1.4 0
Table 2 . Detection
by Immunostaining
ofEosinophil-associated GM-CSF
Treatment Anti-GM-CSF
Medium alone 2.3 ± 1.8
A23187 (60 min) 26 .6 ± 7.7
A23187 (24 h) 30.3 ± 10.5
IFN-y (48 h) 29.0 ± 9.8lease transforming growth factora (4), although its relevance
to allergic inflammation is yet to be determined . GM-CSF,
on the other hand, is a particularly versatile pro-inflamma-
tory mediator that has a wide range of biological activities,
includingthe differentiation ofgranulocytes and macrophage
precursor cells as well as the proliferation of monocytes and
endothelial cells (reviewed in reference 14) . Together with
IL3, GM-CSF is required for the early growth and differen-
Figure 1 . Detection of GM-CSF
mRNA and GM-CSF immunoreac-
tivity in activated human eosinophils .
(A) Positive in situ hybridization with
antisense GM-CSF riboprobe in eo-
sinophils stimulated with IFN-.y (500
U/ml, 48 h) . (B) Similar preparation,
treated with a GM-CSF sense probe
showing no positive hybridization
signals. (C and D) Sub-cellular local-
ization of GM-CSFmRNA in human
eosinophil stimulated with IFN-.y,
stainedwith carbol chromotrope2R (60
min in 1% solution), and visualized by
dark field illumination (C) or phase con-
trast microscopy (D) . (E and F) Immu-
nocytochemical staining of human
eosinophils using an anti-GM-CSF
polyclonal antibody. Positively stained
cells were observed in preparations in-
cubated with IFN-1' (1,000 U/ml, 48
h) (E), but not with medium alone (F) .
tiation of eosinophil precursors (15) . GM-CSF also activates
neutrophils, eosinophils, monocytes, and basophils (14) . There-
fore, in addition to basic proteins and lipid mediator release
(16), GM-CSF may also contribute to eosinophil-mediated
tissue injury. It also raises the possibility of an autocrine mech-
anism, where stimulated eosinophils may both release and
respond to GM-CSF.
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